Submitted by Anonymous (not verified) on 10 October 2023 - 13:59
Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell;Carcinomas, Hepatocellular, Date of authorisation: 09/09/2016, Revision: 18, Status: Authorised
Source: